Willis Towers Watson Public Limited Company - Ordinary Shares (NQ:WTW)

288.61 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Willis Towers Watson Public Limited Company - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Fear & Greed Index Remains In 'Greed' Zone Following Earnings Reports; Dow Jumps Over 100 Points ↗

February 07, 2024

The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed higher on Tuesday, as...

Via Benzinga

Topics Stocks

Willis Towers Stock Pops On Strongest Earnings Growth In A Year ↗

February 07, 2024

Willis Towers stock holds the No. 3 rank among its peers in the 15-stock Insurance-Brokers industry group. It got a rating upgrade Wednesday.

Via Investor's Business Daily

Nasdaq Down 50 Points; Willis Towers Watson Posts Upbeat Profit ↗

February 06, 2024

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded up 0.11% to 38,422.51 while the NASDAQ fell 0.32% to 15,547.61. The S&P...

Via Benzinga

Topics Stocks

Insurance Stocks Moving In Tuesday's Intraday Session ↗

February 06, 2024

Via Benzinga

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

Where Willis Towers Watson Stands With Analysts ↗

October 06, 2023

Via Benzinga

Analyst Ratings for Willis Towers Watson ↗

September 13, 2023

Via Benzinga

Where Willis Towers Watson Stands With Analysts ↗

August 28, 2023

Via Benzinga

Chewy To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Thursday ↗

January 11, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Some Surprise Names Led The S&P 500 In October ↗

November 02, 2023

The best and worst stock performers in the S&P 500 for October include some surprising names.

Via Investor's Business Daily

Topics Stocks

Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets ↗

October 27, 2023

It has been another week of volatility in the stock market, characterized by mounting fears of a wider Middle East conflict and a more cautious fourth-quarter earnings outlook announced by U.S....

Via Benzinga

What 7 Analyst Ratings Have To Say About Willis Towers Watson ↗

August 08, 2023

Via Benzinga

The Latest Analyst Ratings for Willis Towers Watson ↗

July 17, 2023

Via Benzinga

These Analysts Increase Their Forecasts On Willis Towers Watson After Upbeat Earnings ↗

October 27, 2023

Willis Towers Watson Public Limited Company (NASDAQ: WTW) reported better-than-expected third-quarter results on Thursday.

Via Benzinga

How To Earn $500 A Month From Willis Towers Watson Stock Following Upbeat Earnings ↗

October 27, 2023

Willis Towers Watson Public Limited Company (NASDAQ: WTW) reported better-than-expected third-quarter results on Thursday.

Via Benzinga

Insurance Stocks Moving In Thursday's Intraday Session ↗

October 26, 2023

Via Benzinga

Insurance Stocks Moving In Tuesday's Intraday Session ↗

September 19, 2023

Via Benzinga

GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

September 13, 2023

Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in...

Via Benzinga

How Is The Market Feeling About Willis Towers Watson? ↗

July 04, 2023

Via Benzinga

Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

October 26, 2023

Gainers

Via Benzinga

Future Challenges For Willis Towers Watson: Analyst Cautions On Downward EPS Revisions Amid Hiring Headwinds ↗

August 08, 2023

BMO Capital Market analyst Michael Zaremski downgraded Willis Towers Watson PLC (NASDAQ: WTW) to Underperform from Market Perform at a decreased

Via Benzinga

IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday ↗

October 26, 2023

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.

Via Benzinga

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗

August 08, 2023

Via Benzinga

Earnings Scheduled For October 26, 2023 ↗

October 26, 2023

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.

Via Benzinga

Insurance Stocks Moving In Thursday's Intraday Session ↗

July 27, 2023

Via Benzinga

Goldman Sachs Reveals Long-Term AI Portfolio: Here Are The 50 Stocks To Monitor ↗

August 22, 2023

Via Benzinga

Topics Artificial Intelligence

Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023 ↗

July 28, 2023

Via Benzinga

Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 27, 2023

Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023 ↗

June 20, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.